The University of Chicago Header Logo

Daniel Shevrin

Concepts (271)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Prostatic Neoplasms, Castration-Resistant
10
2026
121
2.010
Why?
Prostatic Neoplasms
28
2024
1846
1.360
Why?
Circulating Tumor DNA
1
2026
82
0.850
Why?
Genetic Testing
1
2026
610
0.690
Why?
Biomarkers, Tumor
4
2026
1786
0.600
Why?
Androgen Antagonists
8
2024
157
0.590
Why?
Antineoplastic Combined Chemotherapy Protocols
10
2024
2666
0.500
Why?
Prostate-Specific Antigen
9
2026
356
0.490
Why?
Receptors, Androgen
2
2017
126
0.480
Why?
PTEN Phosphohydrolase
1
2016
154
0.450
Why?
Fatigue
5
2011
187
0.360
Why?
Bone Neoplasms
4
2019
316
0.340
Why?
Aged, 80 and over
16
2026
7461
0.300
Why?
Male
47
2026
47475
0.280
Why?
Neoplasms, Hormone-Dependent
2
2018
35
0.270
Why?
Hypercalcemia
10
1990
60
0.250
Why?
Antineoplastic Agents
7
2019
2386
0.240
Why?
Androstenes
2
2024
42
0.240
Why?
Aged
25
2026
21986
0.240
Why?
Poly(ADP-ribose) Polymerase Inhibitors
2
2024
90
0.230
Why?
Genomics
2
2026
914
0.230
Why?
Testosterone
4
2024
266
0.220
Why?
Quality of Life
9
2022
1904
0.220
Why?
Phthalazines
1
2024
60
0.200
Why?
5-alpha Reductase Inhibitors
2
2014
12
0.200
Why?
Middle Aged
25
2026
29642
0.200
Why?
Taxoids
3
2015
127
0.200
Why?
Feasibility Studies
1
2026
818
0.200
Why?
Neoplasm Metastasis
11
2024
1102
0.190
Why?
Humans
53
2026
98799
0.190
Why?
Thrombin
1
2003
60
0.190
Why?
Piperazines
1
2024
308
0.180
Why?
Prednisone
4
2024
252
0.180
Why?
Surveys and Questionnaires
6
2013
3058
0.180
Why?
Ataxia Telangiectasia Mutated Proteins
2
2024
65
0.170
Why?
Mice, Nude
16
2014
829
0.170
Why?
Carcinoma, Squamous Cell
11
2003
1107
0.160
Why?
Metformin
1
2022
134
0.160
Why?
BRCA2 Protein
2
2024
178
0.160
Why?
DNA Repair
2
2024
363
0.160
Why?
Lung Neoplasms
15
2003
2474
0.160
Why?
BRCA1 Protein
2
2024
222
0.160
Why?
Prospective Studies
3
2026
4837
0.150
Why?
Radium
1
2019
7
0.150
Why?
Urinary Bladder Neoplasms
1
2023
403
0.140
Why?
Etidronic Acid
2
1991
5
0.140
Why?
Kallikreins
1
2017
47
0.130
Why?
Carcinoma, Renal Cell
2
1994
384
0.130
Why?
Cost of Illness
1
2018
165
0.120
Why?
Pain
3
2010
417
0.120
Why?
Finasteride
3
2013
8
0.120
Why?
Neoplasms
4
2007
3382
0.120
Why?
Kidney Neoplasms
2
1994
556
0.120
Why?
Orchiectomy
3
2011
63
0.120
Why?
Urination Disorders
2
2013
52
0.110
Why?
Decorin
1
2014
6
0.110
Why?
Oncolytic Viruses
1
2014
20
0.110
Why?
Calcium
9
2008
1205
0.110
Why?
Oncolytic Virotherapy
1
2014
36
0.110
Why?
Neoplasm Transplantation
11
2014
400
0.110
Why?
Echinomycin
1
1994
2
0.100
Why?
Thioguanine
1
1994
17
0.100
Why?
Steroid 17-alpha-Hydroxylase
1
2014
16
0.100
Why?
Antimetabolites, Antineoplastic
2
2000
246
0.100
Why?
Androgens
4
2024
164
0.100
Why?
Naphthalenes
1
2014
43
0.100
Why?
Imidazoles
1
2014
142
0.100
Why?
Germ-Line Mutation
1
2016
404
0.100
Why?
Urinary Bladder Neck Obstruction
1
2013
26
0.100
Why?
Tumor Suppressor Proteins
2
2015
318
0.090
Why?
Prostate
1
2016
434
0.090
Why?
Pharmacogenetics
1
2016
474
0.090
Why?
Adenocarcinoma
3
2015
1215
0.090
Why?
Prothrombin
2
2003
19
0.080
Why?
Blood Coagulation
2
2003
90
0.080
Why?
Cholestenone 5 alpha-Reductase
1
2010
2
0.080
Why?
Cell Line, Tumor
3
2014
2913
0.080
Why?
Urinary Incontinence
1
2013
226
0.080
Why?
Enzyme Inhibitors
2
2010
641
0.080
Why?
Mitoxantrone
1
2010
65
0.080
Why?
Peptide Fragments
3
2003
480
0.080
Why?
Arabinonucleotides
1
1989
1
0.070
Why?
Vidarabine Phosphate
1
1989
3
0.070
Why?
Survival Rate
5
2015
2057
0.070
Why?
Cisplatin
4
2000
578
0.070
Why?
Hormones
3
2022
138
0.070
Why?
Mice
17
2014
12762
0.070
Why?
Sulfonamides
1
2011
352
0.070
Why?
Antineoplastic Agents, Hormonal
1
2010
161
0.070
Why?
Pyrimidines
1
2011
416
0.070
Why?
Ergocalciferols
1
2008
38
0.070
Why?
Cell Cycle
1
2010
519
0.070
Why?
Trans-Activators
1
2010
447
0.070
Why?
Anorexia
1
2007
26
0.070
Why?
Nitriles
2
2022
172
0.070
Why?
Psychometrics
2
2010
359
0.060
Why?
Epidermal Growth Factor
1
1987
116
0.060
Why?
Treatment Outcome
7
2018
9806
0.060
Why?
Neoplasm Staging
4
2014
2087
0.060
Why?
Thiadiazoles
1
1986
14
0.060
Why?
Nuclear Proteins
1
2010
757
0.060
Why?
Drug Resistance, Neoplasm
1
2010
671
0.060
Why?
Adult
11
2017
29698
0.060
Why?
Disease Models, Animal
6
2014
2581
0.060
Why?
Fluorouracil
2
2000
543
0.060
Why?
Animals
18
2014
29045
0.060
Why?
Plicamycin
1
1985
9
0.060
Why?
Factor Analysis, Statistical
1
2005
119
0.050
Why?
Carcinoma, Small Cell
1
1985
116
0.050
Why?
Abiraterone Acetate
1
2024
14
0.050
Why?
Castration
1
2024
32
0.050
Why?
Stress, Psychological
1
2007
384
0.050
Why?
Time Factors
5
2018
5586
0.050
Why?
Administration, Intravesical
1
2023
41
0.050
Why?
BCG Vaccine
1
2023
44
0.050
Why?
Vinblastine
1
2003
84
0.050
Why?
Health Surveys
1
2003
254
0.050
Why?
Clinical Trials, Phase III as Topic
1
2023
172
0.050
Why?
Carcinoma, Non-Small-Cell Lung
2
2003
1177
0.050
Why?
Mice, Inbred BALB C
4
2014
1113
0.050
Why?
Androgen Receptor Antagonists
1
2022
21
0.040
Why?
Dutasteride
2
2013
5
0.040
Why?
Azasteroids
2
2013
5
0.040
Why?
Reproducibility of Results
2
2010
2799
0.040
Why?
Amino Acids
1
2003
248
0.040
Why?
Phenylthiohydantoin
1
2022
58
0.040
Why?
Mifepristone
1
2022
59
0.040
Why?
Interleukin-6
1
2003
283
0.040
Why?
Registries
2
2018
1133
0.040
Why?
Parathyroid Hormone
4
1990
233
0.040
Why?
Vascular Endothelial Growth Factor A
1
2003
402
0.040
Why?
Benzamides
1
2022
260
0.040
Why?
Receptors, Glucocorticoid
1
2022
145
0.040
Why?
Dihydrotestosterone
2
2010
28
0.040
Why?
Survival Analysis
2
2016
1530
0.040
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2013
889
0.040
Why?
Etoposide
1
2000
207
0.040
Why?
Injections, Subcutaneous
2
1991
142
0.040
Why?
Drug Evaluation
3
1989
109
0.040
Why?
Carboplatin
2
2015
331
0.040
Why?
Drug Therapy, Combination
2
2015
766
0.040
Why?
Randomized Controlled Trials as Topic
1
2023
995
0.040
Why?
Antineoplastic Agents, Phytogenic
1
2000
272
0.040
Why?
Body Mass Index
1
2022
869
0.030
Why?
Public Health Surveillance
1
2018
24
0.030
Why?
Bone and Bones
2
1990
272
0.030
Why?
Proto-Oncogene Proteins c-ets
1
2017
25
0.030
Why?
Antibodies
2
1990
349
0.030
Why?
United States
3
2018
8387
0.030
Why?
Female
9
2007
51997
0.030
Why?
Interviews as Topic
2
2010
390
0.030
Why?
Benzimidazoles
1
2017
120
0.030
Why?
Cell Line
3
1991
2484
0.030
Why?
Physicians
1
2003
687
0.030
Why?
Diarrhea
2
2011
180
0.030
Why?
Biomarkers
1
2003
2026
0.030
Why?
Quality-Adjusted Life Years
1
2016
170
0.030
Why?
Health Care Surveys
1
2016
282
0.030
Why?
Everolimus
1
2015
35
0.030
Why?
Molecular Targeted Therapy
1
2017
331
0.030
Why?
Disease Progression
2
2015
1621
0.030
Why?
Socioeconomic Factors
1
2018
675
0.030
Why?
Research
1
2016
258
0.030
Why?
Neoplasm Grading
1
2016
425
0.030
Why?
Neoplastic Cells, Circulating
1
2015
78
0.030
Why?
Neutropenia
1
2015
211
0.030
Why?
Bone Resorption
3
1990
42
0.030
Why?
Transplantation, Heterologous
3
2010
375
0.030
Why?
Caregivers
1
2016
200
0.030
Why?
Heterografts
1
2014
121
0.030
Why?
Health Care Costs
1
2016
269
0.030
Why?
Gene Transfer Techniques
1
2014
155
0.030
Why?
Proportional Hazards Models
1
2016
925
0.030
Why?
Comorbidity
1
2018
1037
0.030
Why?
Proto-Oncogene Proteins c-akt
1
2015
369
0.030
Why?
TOR Serine-Threonine Kinases
1
2015
224
0.020
Why?
Disease Management
1
2016
378
0.020
Why?
Injections, Intravenous
1
1994
215
0.020
Why?
Kidney
2
1989
1126
0.020
Why?
Climacteric
1
1993
4
0.020
Why?
Goserelin
1
1993
5
0.020
Why?
Osteoclasts
2
1990
36
0.020
Why?
Drug Resistance
1
1994
234
0.020
Why?
Leuprolide
1
1993
34
0.020
Why?
Kaplan-Meier Estimate
1
2015
909
0.020
Why?
Patient Acceptance of Health Care
1
2016
315
0.020
Why?
Databases, Factual
1
2017
1102
0.020
Why?
Sequence Analysis, DNA
1
2016
920
0.020
Why?
Clonidine
1
1993
33
0.020
Why?
Phosphorylation
1
2015
1148
0.020
Why?
Patient Satisfaction
1
2016
519
0.020
Why?
Mice, SCID
1
2013
278
0.020
Why?
Symptom Assessment
1
2013
77
0.020
Why?
Mutation
1
2024
4443
0.020
Why?
Triazoles
1
2013
118
0.020
Why?
Follow-Up Studies
2
2015
4049
0.020
Why?
Retrospective Studies
2
2017
11104
0.020
Why?
Case-Control Studies
1
2016
2017
0.020
Why?
United States Department of Defense
1
2011
4
0.020
Why?
Age Factors
1
2016
1976
0.020
Why?
Early Termination of Clinical Trials
1
2011
16
0.020
Why?
Tumor Cells, Cultured
2
1993
1029
0.020
Why?
Indazoles
1
2011
65
0.020
Why?
Dose-Response Relationship, Drug
2
2003
1949
0.020
Why?
Urology
1
2013
145
0.020
Why?
Cell Movement
1
2014
821
0.020
Why?
Universities
1
2011
166
0.020
Why?
Tissue Extracts
1
1990
24
0.020
Why?
Patient Compliance
1
2011
247
0.020
Why?
Confidence Intervals
1
2010
221
0.020
Why?
Health Status Indicators
1
2010
99
0.020
Why?
Self Concept
1
2010
141
0.020
Why?
Area Under Curve
1
2010
341
0.020
Why?
25-Hydroxyvitamin D3 1-alpha-Hydroxylase
1
1989
10
0.020
Why?
Steroid Hydroxylases
1
1989
13
0.020
Why?
Cell Division
1
2010
690
0.020
Why?
Immunohistochemistry
1
2013
1818
0.020
Why?
Specific Pathogen-Free Organisms
1
1989
85
0.020
Why?
Medical Oncology
1
2013
426
0.020
Why?
Estradiol
1
2010
268
0.020
Why?
Data Collection
1
2010
376
0.020
Why?
Weight Loss
1
2010
247
0.020
Why?
Prognosis
1
2016
4139
0.020
Why?
Pain Measurement
1
2010
403
0.020
Why?
Oncogenes
1
1988
102
0.020
Why?
Laryngeal Neoplasms
1
1988
89
0.020
Why?
Gene Amplification
1
1988
142
0.020
Why?
Calcitriol
1
1989
174
0.020
Why?
Xenograft Model Antitumor Assays
1
2010
559
0.020
Why?
Carnitine
1
1987
15
0.020
Why?
Thymectomy
1
1987
31
0.020
Why?
Cell Proliferation
1
2013
1801
0.020
Why?
Anxiety
1
2010
376
0.020
Why?
Risk Factors
1
2018
6295
0.020
Why?
Chicago
1
2011
1520
0.020
Why?
Ambulatory Care
1
2007
203
0.010
Why?
Data Interpretation, Statistical
1
2007
312
0.010
Why?
Neoplasm Proteins
1
1988
553
0.010
Why?
ROC Curve
1
2007
797
0.010
Why?
Gene Expression Regulation, Neoplastic
1
2010
1400
0.010
Why?
Proteins
1
1990
804
0.010
Why?
Doxorubicin
1
1985
285
0.010
Why?
Double-Blind Method
1
2008
1793
0.010
Why?
Longitudinal Studies
1
2007
1305
0.010
Why?
Safety
1
2003
138
0.010
Why?
Maximum Tolerated Dose
1
2003
265
0.010
Why?
Hematologic Diseases
1
2000
77
0.010
Why?
Parathyroid Hormone-Related Protein
2
1990
11
0.010
Why?
Cause of Death
1
2000
279
0.010
Why?
Immunoassay
1
1999
102
0.010
Why?
Head and Neck Neoplasms
1
1985
1091
0.010
Why?
Microscopy, Electron
2
1990
435
0.010
Why?
Remission Induction
1
2000
764
0.010
Why?
Reference Values
2
1989
608
0.010
Why?
Pilot Projects
1
2000
978
0.010
Why?
Phosphorus
2
1989
119
0.010
Why?
Venous Thrombosis
1
1999
265
0.010
Why?
Adolescent
1
2007
10168
0.010
Why?
Neoplasm Recurrence, Local
1
2000
1538
0.010
Why?
Infusions, Intravenous
1
1993
403
0.010
Why?
Diabetes Mellitus
1
1999
815
0.010
Why?
Pregnancy
1
1999
3286
0.010
Why?
Neoplasm Invasiveness
1
1993
583
0.010
Why?
Osteoblasts
1
1990
97
0.000
Why?
Osteocytes
1
1988
8
0.000
Why?
Teriparatide
1
1988
12
0.000
Why?
Cattle
1
1988
398
0.000
Why?
Cyclic AMP
1
1988
277
0.000
Why?
Minerals
1
1984
21
0.000
Why?
Magnesium
1
1984
175
0.000
Why?
Spine
1
1984
149
0.000
Why?
Shevrin's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (271)
Explore
_
Co-Authors (11)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_